Class: Expansion (424)
Protection of hemopoietic cells during chemotherapy or radiotherapy
Patent Number: 5595973This patent is useful in the treatment of patients with radiation or chemotherapy. Since hematopoietic stem cell toxicity is usually the dose limiting factor in radiation or chemotherapy, this patent teaches a way how to overcome this. Specifically, the patent claims inhibiting hematopoietic stem cell proliferation through administration of AcSDKP, then providing the chemotherapy and/or...
Methods for using the obese product to stimulate hematopoietic development
Patent Number: 6838079Leptin is a natural inhibitor of fat. When you knock out leptin gene, mice are extremely obese. Interestingly, leptin has numerous other functions in the body, including stimulation of inflammatory responses, as well as immunologically predisposing to Th1. In this patent the inventors identified that leptin stimulates hematopoiesis. This patent may be useful for treatment of...
Methods for using the obese gene and its gene product to stimulate hematopoietic development
Patent Number: 6355237Leptin inhibits obesity. In this patent leptin is used in combination with other hematopoietic cytokines for the stimulation of hematopoietic stem cell function. Given the similarity between hematopoietic stem cells and neuronal stem cells, it would be interesting to assess the effects of leptin on neuronal stem cells.
Protection of hemopoietic cells
Patent Number: 5739110This patent covers the use of the peptide AcSDKP for inhibiting hematopoietic stem cell proliferation and protecting the stem cells from radiation or chemotherapy. In addition, since the angiotensin-converting enzyme is responsible for degradation of AcSDKP, inhibition of ACE by clinically used inhibitors for the inhibition of hematopoiesis is provided.
Method of screening a compound for hematopoietic activity
Patent Number: 5965437This patent teaches the in vitro purification of early hematopoietic stem cells by killing of the mature ones. This is performed through addition of a hematopoietic growth factor, together with a cytotoxic agent that only kills dividing cells. The hematopoietic stem cells that are very primitive will not be killed since the primitive hematopoietic stem cells do not undergo division very...
Use of interferon .gamma. for the inhibition of proliferation and differentiation of primitive hematopoietic progenitor cells
Patent Number: 5807744This patent teaches that the Th1 cytokine interferon gamma inhibits proliferation of hematopoietic stem cells. In one use, this cytokine may be administered to cultures of bone marrow harvested from cancer patients for autologous transplant, the administration of interferon gamma would protect the stem cells from chemotherapy which would kill residual cancer cells. Additionally, the...
Controlling proliferation of cells before and after encapsulation in a bioartificial organ by gene transformation
Patent Number: 5843431This patent covers the use of certain compositions of matter for the generation of implantable cells and stem cells. In some embodiments the cells are treated so as to not elicit an immune response. In other embodiments the proliferation of the cells in the encapsulation devices is controlled.
Recombinant primate granulocyte macrophage-colony stimulating factor
Patent Number: 5942221This patent covers primate G-CSF. G-CSF is a potent stimulator of granulocyte production and is used clinically under the name Neupogen and more recently Neulasta.
In vitro growth of functional islets of Langerhans and in vivo uses thereof
Patent Number: 6001647This patent teaches how to expand populations of islet cells in vitro for possible in vivo use in the treatment of type 1 diabetes. This technology seems very exciting, however the patent has some priority claims more than a decade ago and to our knowledge this therapy has yet to be clinically implimented.
In vitro growth of functional islets of Langerhans
Patent Number: 5834308This the success of the Edmonton Protocol for treating diabetes using allogeneic islets, the need for sources of islet cells has intensified. The patent addresses that need through teaching ways of growing and expanding islet cells from pancreatic stem cells.